The ocrelizumab phase II extension trial suggests the potential to improve the risk:benefit balance in multiple sclerosis.

Publication date: Available online 8 June 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Prof David Baker, Gareth Pryce, Louisa K. James, Monica Marta, Klaus Schmierer
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research